Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs
Travera Inc
Travera Inc
Washington University School of Medicine
Global BioClinical
University of California, Irvine
Bristol-Myers Squibb
VA Office of Research and Development
Masonic Cancer Center, University of Minnesota
National Institutes of Health Clinical Center (CC)
SWOG Cancer Research Network
Northwestern University
M.D. Anderson Cancer Center